In the News > Dyax Opens Headquarters at Network Drive, Becomes Burlington’s First Biopharmaceutical Company

Dyax Opens Headquarters at Network Drive, Becomes Burlington’s First Biopharmaceutical Company

4/2/2012

BOSTON — Nordblom Company announced that Dyax Corp. (NASDAQ:DYAX) has opened its new corporate headquarters in Network Drive at Northwest Park. Their 45,000-square-foot first class office and lab space in 55 Network Drive is the result of an extensive build out featuring office areas and laboratory facilities.
 
Dyax moved from 300 Technology Square in Cambridge to the world class campus in amenities rich Burlington, and is the first biopharmaceutical company to be located in this vibrant suburban town. Dyax was represented by Peter Bekarian and Bryan Sparkes, and the landlord by Tamie Thompson and Tyler Spring all of Jones Lang LaSalle.

“We are very pleased to be in our new corporate headquarters at Network Drive after an extensive search for the right location,” said Gustav Christensen, President and Chief Executive Officer of Dyax. “The facility reflects our culture, and the Park is the ideal environment for us to carry out our business plan going forward.”

“We are delighted to welcome Dyax to the already impressive line-up of tenants at Network Drive. It is a testament to the quality and flexibility of the campus and its appeal to the innovative companies found in Massachusetts,” stated Ogden Hunnewell, Executive Vice President/Partner of Nordblom Company.

Dyax’s space offers a flexible, collaborative office and lab environment. It accommodates the biopharmaceutical company’s innovative technology with: laboratory, office and conference space. Jones Lang LaSalle was the project’s Construction Manager for their interior build out.

Network Drive at Northwest Park is a 1 million-square-foot office campus situated on 158 acres. It is one of the largest and most advanced office parks along the entire Route 128/I-95 corridor and is located directly on Route 3 at the I-95 intersection. It consists of an exceptional multi-tenanted office park, comprising seven buildings in a dramatic landscaped setting. In addition to Dyax Corp., other companies which have established headquarter locations at Network Drive at Northwest Park include: Avid Technologies, Palomar Medical, Exa Corporation, e-Dialog and Memento, as well as a large regional office for Oracle Corporation, bringing the campus to over 90% leased with enough land to build nearly 300,000SF of additional development. The campus has three entrances from Network Drive, and an amenity package that includes a central “Winter Garden” featuring quality indoor and outdoor cafeteria dining, TV and game lounges , an ATM, a putting green, access to conference facilities and much more. The campus also boasts a comprehensive exercise facility with locker rooms.

About Dyax Dyax is a fully integrated biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs. Dyax's lead product, ecallantide, has been approved under the brand name KALBITOR® in the United States for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older.
Dyax is commercializing KALBITOR in the United States independently, and establishing strategic collaborations to develop and commercialize ecallantide for the treatment of HAE in key regions worldwide. Currently, Dyax has agreements for regions including Europe, Japan, Russia, the Middle East, Israel, North Africa, Australia, New Zealand, Latin America (excluding Mexico) and the Caribbean. Dyax is also exploring other potential indications for ecallantide, either alone or through collaborations, including drug-induced angioedema.

Ecallantide and other compounds in Dyax's pipeline were identified using its patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly through the Licensing and Funded Research Program (LFRP), which has approximately 70 revenue generating licenses and collaborations for therapeutic discovery, as well as for affinity separations, diagnostic imaging, and research reagents. The success of the Company's LFRP portfolio is illustrated by the program's advanced licensee pipeline that includes 18 candidates in clinical development. Of those candidates, four are in Phase 3 clinical trials, four are in Phase 2 and ten are in Phase 1.

Dyax is headquartered in Burlington, Massachusetts.